The earnings call highlighted significant achievements, including FDA approval and strong market reception for CGuard Prime, alongside successful financing efforts. However, financial challenges such as decreased gross profit, increased operating expenses, and a delay in product launch were also noted.

Company Guidance -

Q3 2025

During the InspireMD Second Quarter 2025 Earnings Call, the company provided guidance highlighting significant progress and future plans. InspireMD announced the FDA premarket approval for its CGuard Prime Carotid Stent System, marking a transformative milestone in its history. This approval sets the stage for a U.S. commercial launch, supported by a foundation of experience from over 30 international markets and more than 60,000 patients treated. The company's goal is to lead the U.S. carotid interventional market with its innovative stent platform, aimed at lowering the risk of strokes and major adverse events. InspireMD is strategically executing its commercial playbook, with successful approvals and orders in numerous U.S. accounts. The company is also advancing its clinical pipeline with pivotal studies, including C-GUARDIANS II and III, targeting TCAR procedures, and a feasibility study in acute stroke care. Financially, InspireMD reported a 2% increase in Q2 2025 revenue to $1.8 million, although gross profit slightly decreased. The company strengthened its cash position with over $58 million in gross proceeds from financing events, supporting its growth strategy and commercial launch. While not providing specific guidance, InspireMD is focused on building a strong foundation for future expansion and profitability.

FDA Premarket Approval for CGuard Prime

InspireMD received FDA premarket approval for CGuard Prime Carotid Stent System, marking a significant milestone and starting the U.S. commercial launch.

Successful Financing and Strong Cash Position

InspireMD raised $40.1 million through a private placement and $17.9 million from warrant exercises, strengthening the cash position by over $58 million.

Strong Early U.S. Market Reception

Following FDA approval, InspireMD completed procedures with double-digit U.S. physicians and secured stocking orders, indicating strong early market interest.

Progress in Clinical Pipeline

Enrollment continues for pivotal studies C-GUARDIANS II and III, and the tandem lesion study is halfway complete, indicating progress in expanding the use of CGuard Prime.

InspireMD (NSPR) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

NSPR Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 11, 2025	2025 (Q3)	-0.20 / -	-0.16	―	―	―
Aug 05, 2025	2025 (Q2)	-0.26 / -0.26	-0.22	-18.18% (-0.04)	―
May 09, 2025	2025 (Q1)	-0.20 / -0.22	-0.21	-4.76% (-0.01)	―
Mar 12, 2025	2024 (Q4)	-0.20 / -0.19	-0.16	-18.75% (-0.03)	―
Nov 12, 2024	2024 (Q3)	-0.20 / -0.16	-0.15	-6.67% (-0.01)	―
Aug 06, 2024	2024 (Q2)	-0.19 / -0.22	-0.24	8.33% (+0.02)	―
May 14, 2024	2024 (Q1)	-0.18 / -0.21	-0.53	60.38% (+0.32)	―
Mar 06, 2024	2023 (Q4)	-0.19 / -0.16	-0.6	73.33% (+0.44)	―
Nov 06, 2023	2023 (Q3)	-0.14 / -0.15	-0.58	74.14% (+0.43)	―
Aug 08, 2023	2023 (Q2)	-0.43 / -0.24	-0.59	59.32% (+0.35)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

NSPR Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 05, 2025	$2.67	$2.45	-8.24%
May 09, 2025	$2.60	$2.60	0.00%
Mar 12, 2025	$2.79	$2.81	+0.72%
Nov 12, 2024	$2.46	$2.38	-3.25%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does InspireMD Inc (NSPR) report earnings?

InspireMD Inc (NSPR) is schdueled to report earning on Nov 11, 2025, TBA (Confirmed).

What is InspireMD Inc (NSPR) earnings time?

InspireMD Inc (NSPR) earnings time is at Nov 11, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is NSPR EPS forecast?

NSPR EPS forecast for the fiscal quarter 2025 (Q3) is -0.2.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing